Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta-d-Glucan Levels?

Juergen Prattes; Reinhard B Raggam; Kim Vanstraelen; Jasmin Rabensteiner; Christoph Hoegenauer; Robert Krause; Florian Prüller; Albert Wölfler; Isabel Spriet; Martin Hoenigl

doi:10.1128/JCM.02972-15

Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta-d-Glucan Levels?

J Clin Microbiol. 2016 Mar;54(3):798-801. doi: 10.1128/JCM.02972-15. Epub 2015 Dec 30.

Authors

Affiliations

¹ Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria Center for Biomarker Research in Medicine, Graz, Austria.
² Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria martin.hoenigl@medunigraz.at reinhard.raggam@medunigraz.at.
³ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences University Hospital Leuven, Leuven, Belgium.
⁴ Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
⁵ Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
⁶ Division of Hematology, Medical University of Graz, Graz, Austria.
⁷ Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria Center for Biomarker Research in Medicine, Graz, Austria Division of Infectious Diseases, Department of Medicine, University of California, San Diego, San Diego, California, USA Division of Pulmonology, Medical University of Graz, Graz, Austria martin.hoenigl@medunigraz.at reinhard.raggam@medunigraz.at.

Abstract

Blood citrulline and intestinal fatty acid binding protein were determined as biomarkers for intestinal mucositis. Biomarker levels were correlated with corresponding serum 1,3-beta-D-glucan levels in 56 samples obtained from 33 cases with underlying hematological malignancies receiving induction chemotherapy. No correlation between biomarkers of intestinal mucositis and BDG levels was observed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01576653.).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Biomarkers
False Positive Reactions
Female
Hematologic Neoplasms / complications
Hematologic Neoplasms / drug therapy
Humans
Intestinal Mucosa / drug effects*
Intestinal Mucosa / pathology*
Male
Middle Aged
Mucositis / blood
Mucositis / diagnosis*
Mucositis / etiology*
Sensitivity and Specificity
Young Adult
beta-Glucans / blood

Substances

Antineoplastic Agents
Biomarkers
beta-Glucans
beta-1,3-glucan

Associated data

ClinicalTrials.gov/NCT01576653

Grants and funding

The funders had no role in the study design, data collection, analysis, interpretation, or decision to publish, in the writing of the manuscript, or in the decision to submit the manuscript for publication.